An association has been reported between high mu-opioid receptor expression and poorer survival in patients with prostate cancer [273] and a correlation between increased plasma beta-END levels and improved quality of life in patients with breast cancer [151]. This evidence concerns the gene OPRM1 and prostate cancer.